Metformin Inhibits Prostate Cancer Progression via Regulation of the AKT/mTOR Signaling Pathway

Zhang Zhengkun, Quan Zhiyou, Dai Panpan, Xu Keyi, Yin Zhaoru, Chen Dan, Geng Ruiman, Ji Xuxu, Wang Dingxue, Chen Shu

Abstract

Objective 

To investigate the effects of metformin on the proliferation, migration, and invasion of prostate cancer cells, and to determine whether its antitumor effects are mediated by regulation of human antigen R (HuR) and the AKT/mammalian target of rapamycin (mTOR) signaling pathway.

Methods 

Human prostate cancer cell lines PC3 and 22RV1 were used as the research models and were treated with metformin. HuR knockdown and overexpression experiments were performed to further verify the underlying mechanism. Cell proliferation was assessed using the cell counting kit-8 (CCK-8) assay. Cell migration and invasion were evaluated by Transwell assays. The expression levels of HuR and AKT/mTOR pathway-related proteins were measured by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting.

Results 

Metformin treatment reduced the proliferation, migration, and invasion abilities of PC3 and 22RV1 cells, and inhibited the expression of proteins associated with the AKT/mTOR signaling pathway (P < 0.05). HuR knockdown also decreased the proliferation, migration, and invasion abilities of prostate cancer cells and inhibited AKT/mTOR pathway activity. In contrast, HuR overexpression partially attenuated the inhibitory effects of metformin on the malignant biological behaviors of prostate cancer cells and its inhibitory effects on the AKT/mTOR signaling pathway. In addition, metformin downregulated HuR mRNA and protein expression levels in PC3 and 22RV1 cells in a concentration-dependent manner (P < 0.01).

Conclusion 

Metformin may inhibit the activation of the AKT/mTOR signaling pathway by downregulating HuR expression, thereby reducing the proliferation, migration, and invasion of prostate cancer cells.

 

Keywords: Prostate cancer, Metformin, Humanantigen R, AKT, mTOR

 

Full Text:

PDF


References


Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229. DOI: 10. 3322/caac.21834.

Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47. DOI: 10.1016/j.jncc.2024.01.006.

Dutta S, Shah R B, Singhal S, et al. Metformin: a review of potential mechanism and therapeutic utility beyond diabetes[J]. Drug Des Devel Ther, 2023, 17: 1907-1932. DOI: 10.2147/DDDT.S409373.

Evans J M, Donnelly L A, Emslie-Smith A M, et al. Metformin and reduced risk of cancer in diabetic patients[J]. BMJ, 2005, 330(7503): 1304. DOI: 10.1136/bmj.38415.708634.F7.

Tsai K W, Liao J B, Tseng H W. Metformin regulates the proliferation and motility of melanoma cells by modulating the LINC00094/miR-1270 axis[J/OL]. Cancer Cell Int, 2024, 24(1): 384. https://doi.org/10.1186/s12935-024-03545-5.

Yang J, Zhou Y, Xie S, et al. Metformin induces ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer[J/OL]. J Exp Clin Cancer Res, 2021, 40(1): 206. https://doi.org/10.1186/s13046-021-02012-7.

Gholami M, Klashami Z N, Ebrahimi P, et al. Metformin and long non-coding RNAs in breast cancer[J/OL]. J Transl Med, 2023, 21(1): 155. https://doi.org/10.1186/s12967-023-03909-x.

García-Sáenz M, Lobaton-Ginsberg M, Ferreira-Hermosillo A. Metformin in differentiated thyroid cancer: molecular pathways and its clinical implications[J/OL]. Biomolecules, 2022, 12(4): 574. https://doi.org/10. 3390/biom12040574.

Ahn H K, Lee Y H, Koo K C. Current status and application of metformin for prostate cancer: a comprehensive review[J/OL]. Int J Mol Sci, 2020, 21(22): 8540. https://doi.org/10.3390/ijms21228540.

Kincius M, Patasius A, Linkeviciute-Ulinskiene D, et al. Reduced risk of prostate cancer in a cohort of Lithuanian diabetes mellitus patients[J]. Aging Male, 2020, 23(5): 1333. DOI: 10.1080/13685538.2020.1766013.

Salt I P, Nunes J R C, Fullerton M D. Metformin again? Atheroprotection mediated by macrophage AMPK and ATF1[J]. Cardiovasc Res, 2021, 117(5): 1233. DOI: 10.1093/cvr/cvab065.

Roy A, Sahoo J, Kamalanathan S, et al. Diabetes and pancreatic cancer: exploring the two-way traffic[J]. World J Gastroenterol, 2021, 27(30): 4939. DOI: 10.3748/wjg.v27.i30.4939.

Li L, Miao H, Chang Y, et al. Multidimensional crosstalk between RNA-binding proteins and noncoding RNAs in cancer biology[J]. Semin Cancer Biol, 2021, 75: 84. DOI: 10.1016/j.semcancer.2021.03.007.

Gebauer F, Schwarzl T, Valcarcel J, et al. RNA-binding proteins in human genetic disease[J]. Nat Rev Genet, 2021, 22(3): 185. DOI: 10.1038/s41576-020-00302-y.

Clark M E, Farinha A, Morrison A R, et al. Structural, biological, and biomedical implications of mRNA interactions with the master regulator HuR[J/OL]. NAR Mol Med, 2025, 2(1): ugaf002. https://doi.org/10.1093/narmme/ugaf002.

Finan J M, Sutton T L, Dixon D A, et al. Targeting the RNA-binding protein HuR in cancer[J]. Cancer Res, 2023, 83(21): 3507. DOI: 10.1158/ 0008-5472.CAN-23-0972.

Chen J, Wu Y, Luo X, et al. Circular RNA circRHOBTB3 represses metastasis by regulating the HuR-mediated mRNA stability of PTBP1 in colorectal cancer[J]. Theranostics, 2021, 11(15): 7507. DOI: 10.7150/thno.59546.

Wei L, Kim S H, Armaly A M, et al. RNA-binding protein HuR inhibition induces multiple programmed cell death in breast and prostate cancer[J/OL]. Cell Commun Signal, 2024, 22(1): 580. https://doi.org/10. 1186/s12964-024-01916-z.

Saraei P, Asadi I, Kakar M A, et al. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances[J]. Cancer Manag Res, 2019, 11: 3295. DOI: 10.2147/CMAR. S200059.

Mei A Y, Mao J H, Ma L, et al. Research progress on metformin in the treatment of diabetes mellitus complicated with pancreatic cancer[J]. Drug Eval Res, 2025, 48(11): 3409. DOI: 10.7501/j.issn.1674-6376.2025.11.032.

Kim Y S, Choi E A, Lee J W, et al. Metformin use reduced the overall risk of cancer in diabetic patients: a study based on the Korean NHIS-HEALS cohort[J]. Nutr Metab Cardiovasc Dis, 2020, 30(10): 1714. DOI: 10.1016/j. numecd.2020.05.010.

Bai P D, Zhang W Z, Xie S Q, et al. Mechanism of metformin regulating tumor cell proliferation and apoptosis through PKM2 to affect prostate cancer invasion and metastasis[J]. J Clin Urol, 2022, 37(11): 846. DOI: 10. 13201/j.issn.1001-1420.2022.11.009.

Luo H F, Yang X K, Chen Y J, et al. Research progress on metformin in the treatment of prostate cancer[J]. J Clin Med Pract, 2023, 27(20): 142. DOI: 10.7619/jcmp.20231475.

Tan X T. A retrospective study of metformin in prostate cancer[D]. Chongqing: Army Medical University, 2022. DOI: 10.27001/d.cnki.gtjyu. 2022.000065.

Lopez D S, Polychronopoulou E, Abdelgadir O, et al. Effects of metformin on cancer survival among men diagnosed with advanced prostate cancer treated with androgen-deprivation therapy: Emulating a target trial[J/OL]. Cancers (Basel), 2025, 17(21): 3579. DOI: 10.3390/cancers17213579.

Gebrael G, Chehade C H, Agarwal N. Metformin in prostate cancer[J]. Lancet Oncol, 2025, 26(8): 982. DOI: 10.1016/S1470-2045(25)00291-8.

Liu Y, Zhang Q, Huang X. Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: Integrating evidence from real-world studies[J]. Prostate Cancer Prostatic Dis, 2025, 28(1): 210. DOI: 10. 1038/s41391-024-00871-7.

Majumder M, Chakraborty P, Mohan S, et al. HuR as a molecular target for cancer therapeutics and immune-related disorders[J/OL]. Adv Drug Deliv Rev, 2022, 188: 114442. https://doi.org/10.1016/j.addr.2022.114442.


Refbacks

  • There are currently no refbacks.